What's the Difference Between Mounjaro and Wegovy?

  • Both Wegovy (semaglutide) and Mounjaro (tirzepatide) available from £79.99 through GPhC #9012878 regulated pharmacy
  • Clear mechanism differences: Wegovy targets GLP-1 receptors while Mounjaro targets both GIP and GLP-1 receptors
  • Practical storage advantage: Wegovy maintains potency for 6 weeks at room temperature vs Mounjaro's 21 days
  • 3-minute online assessment with next-day cold-chain delivery once approved by UK prescribers
Start free consultation

Treatment from £144.99

Takes under 2 minutes · 100% online
Person enjoying the outdoors

Check if you're eligible

Height 175 cm
Weight 82 kg
Your BMI
26.8
Check with prescriber
Start free consultation
Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.
100% UK-based pharmacy Free advice & support Rated Excellent 2,400+ reviews
Which route suits you

Two clinically backed paths to results

A weekly GLP-1 injection or a daily capsule — each fully overseen by our UK pharmacy team, with no obligation to continue.

Treatment
Avg. weight loss
05%10%15%20%25%
Availability
Injection
Weekly pen · GLP-1
Avg. weight loss
~20%up to
Availability Available now
Pill NEW
Daily tablet · Oral GLP-1
Avg. weight loss
~17%up to
Availability Explore now
Live Pricing

Our Range

Prices update live and may change. The live table below always takes precedence.
All treatment is subject to a prescriber consultation and clinical approval.

Compare Mechanisms, Doses and UK Availability

Understanding What the Difference Between Mounjaro and Wegovy Means for UK Patients

When evaluating what the difference between Mounjaro and Wegovy involves, the primary distinction lies in their molecular mechanisms and regulatory pathways in the UK. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, which works as a dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.

Both treatments require prescription-only medicine authorisation through proper clinical channels, but their availability patterns differ across UK healthcare providers. EverydayMeds maintains consistent stock of genuine Novo Nordisk Wegovy through our GPhC #9012878 registered pharmacy, ensuring patients can access treatment without the supply interruptions that sometimes affect other weight management medications. The difference between these mechanisms may influence which treatment your prescriber recommends based on your individual medical history and treatment goals.

Pricing Structure and Value Comparison for UK Online Orders

Understanding what the difference between Mounjaro and Wegovy costs UK patients reveals significant pricing variations across the dose escalation journey. Wegovy pricing at EverydayMeds starts at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our FIRST40 discount code for new customers and DOSE25 for returning patients apply at checkout to reach these final prices.

Bundle options provide convenience for patients planning their treatment journey, with our Intro Duo (0.25mg and 0.5mg combined) priced at £169.99 and the Ultimate Stability Trio offering three months of 2.4mg maintenance supply for £649.99. These bundles eliminate the need for multiple orders and ensure treatment continuity through assured cold-chain storage and delivery. The structured pricing reflects the dose escalation protocol essential for minimising side effects during treatment initiation.

Clinical Evidence Comparing Wegovy and Mounjaro Efficacy

What the difference between Mounjaro and Wegovy demonstrates in clinical trials reflects their distinct mechanisms of action, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Wegovy's evidence base includes the landmark STEP trials, with STEP 1 showing participants achieved approximately 15% average weight reduction at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The recent SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events among patients taking Wegovy.

Mounjaro's SURMOUNT trial programme evaluated tirzepatide's dual-receptor approach, though comparing percentage outcomes directly would be misleading given the different trial methodologies and endpoints used. Both medications require combination with lifestyle modifications and demonstrate their effectiveness through different pathways - Wegovy through established GLP-1 mechanisms and Mounjaro through its novel dual-agonist approach targeting additional metabolic pathways.

How Wegovy's GLP-1 Mechanism Differs from Mounjaro's Dual Action

Wegovy works as a selective GLP-1 receptor agonist, binding to receptors in your brain's appetite centres to reduce hunger signals and increase feelings of fullness after eating smaller portions. This mechanism slows gastric emptying, meaning food stays in your stomach longer, contributing to sustained satiety between meals. The treatment may also reduce food cravings by influencing reward pathways in the brain associated with eating behaviour. Unlike Mounjaro's dual-receptor approach, Wegovy focuses specifically on the well-established GLP-1 pathway that naturally regulates appetite and glucose metabolism. This targeted mechanism has been extensively studied across multiple clinical programmes, providing robust evidence for its role in supporting long-term weight management when combined with dietary modifications and physical activity.

Streamlined UK Ordering Process for Both Treatments

Accessing either treatment through EverydayMeds follows our regulated three-step process designed for UK patients seeking prescription-only weight management support. The initial 3-minute online clinical assessment captures your medical history, current medications, and treatment goals to ensure safe prescribing practices. Your assessment undergoes review by our qualified prescribers within 3 working days (or 24 hours with express service), who evaluate suitability based on MHRA licensing criteria and NICE guidelines. Once approved, your treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity from our GPhC-registered pharmacy directly to your address. This process ensures compliance with UK pharmaceutical regulations while providing convenient access to genuine Novo Nordisk Wegovy or equivalent Mounjaro treatment through proper clinical oversight.

Storage and Practical Usage Differences

What the difference between Mounjaro and Wegovy means for daily management includes important storage considerations that affect treatment convenience and travel flexibility. Wegovy maintains its potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature stability period. Both treatments require initial refrigeration at 2-8°C and use similar pre-filled pen injection systems, though Wegovy's FlexTouch pen design offers specific dose accuracy features developed by Novo Nordisk. The weekly injection schedule remains consistent between treatments, with both requiring dose escalation protocols to minimise gastrointestinal side effects during treatment initiation. This storage advantage makes Wegovy particularly suitable for patients who travel frequently or prefer more flexible medication management without compromising treatment effectiveness.

UK Regulatory Status and Prescription Requirements for Online Access

The regulatory landscape surrounding what the difference between Mounjaro and Wegovy means for UK patients involves distinct MHRA licensing pathways and clinical governance requirements. Wegovy received MHRA approval specifically for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, alongside adolescents over 12 years weighing more than 60kg. NICE recommendation TA875 supports Wegovy use within specialist weight management services, providing additional clinical validation for its effectiveness.

Both treatments require prescription-only medicine authorisation through qualified healthcare providers, with EverydayMeds operating under GPhC registration #9012878 to ensure compliance with UK pharmaceutical regulations. Our clinical team evaluates each assessment against MHRA licensing criteria, ensuring appropriate patient selection and ongoing safety monitoring throughout treatment. This regulatory framework protects patients while enabling convenient online access to genuine treatments through proper clinical oversight.

Making Your Treatment Decision with Expert Clinical Support

Ultimately, what the difference between Mounjaro and Wegovy means for your weight management journey depends on individual factors including medical history, lifestyle preferences, and treatment response patterns that qualified prescribers evaluate during clinical assessment. Both treatments are available through EverydayMeds, and your prescriber can help determine which option aligns best with your specific circumstances and treatment goals. Our clinical team considers factors including previous treatment responses, concurrent medications, and practical preferences when making prescribing recommendations.

To begin your assessment for either treatment, complete our online clinical questionnaire and use discount code FIRST40 (new customers) or DOSE25 (returning patients) at checkout. Visit https://everydaymeds.co.uk/collections/wegovy to start your journey with genuine pharmaceutical support, regulated clinical oversight, and next-day delivery convenience. Our GPhC-registered pharmacy ensures you receive authentic treatment with proper storage, handling, and ongoing clinical support throughout your weight management journey.

Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026

NEW

GLP-1, now in adaily pill

Meet the daily GLP-1 tablet — needle-free, taken on your schedule, and prescribed by UK pharmacists. Designed for flexibility.

Join the free waitlist
Track your progress

Your journey,in your pocket

Track Now

Meet the newGLP-1 pill

  • Once-daily tablet · room-temp storage
  • No needles, no fridge
  • Up to ~15–17% in trials
How treatment works

How GLP-1 treatments help

Reduces appetite

Helps you feel fuller, sooner — so portions naturally shrink.

Curbs cravings

Quietens food noise so snacking and cravings ease off.

Slows digestion

Food stays in your stomach longer, steadying hunger between meals.

Steady blood sugar

Supports more stable glucose levels through the day.

Is GLP-1 treatment right for you?

GLP-1 medicines are powerful and prescription-only for good reason. They suit many people very well — and they aren’t appropriate for everyone. Here’s a clear, honest picture before you decide.

You may be suitable

Criteria met
BMI of 30 or higher
BMI of 27+ with weight-related conditions
Struggled to lose weight with diet alone
Ready to pair with lifestyle changes

Speak to us first

Potential risk
Pregnant, trying to conceive, or breastfeeding
History of certain thyroid cancers
Certain pancreatic or digestive conditions
Under the age of 18

Ready to start your journey?

Track your progress

Your journey, in your pocket

Track your journey

Log every dose and watch your progress build.

Download now Free to download — takes a minute to set up. App Store and Google Play

AI Meal Tracking. Built for GLP-1 Appetites.

Point your camera at any meal and in 4–6 seconds it logs the calories, macros, weight, and fullness it expects.

Never miss a dose

A daily nudge keeps you on track.

How it works

Achieve your goals in just a few simple steps.

Step 1

Start Free Consultation

Select safe UK treatments. Quick answers.

Step 2

Review By Our Clinical Team

Our expert team will use your consultation as the basis of our recommendation and communicate with you.

Step 3

Get it delivered fast

We’ll deliver direct to you, as quickly as tomorrow.

Trusted by thousands

Real people, real change

Hannah M.
Lost 2 st 4 lb in a year

“The cravings that used to run my evenings just quietened down. Having a pharmacist to message made it feel safe.”

David O.
Lost 3 st in a year

“Discreet, simple and genuinely supportive. The dose steps were explained clearly every time.”

Priya S.
Lost 1 st 9 lb in a year

“I finally feel like food isn’t the loudest thing in my head. The delivery was always discreet and on time.”

Frequently asked questions